Matches in Wikidata for { <http://www.wikidata.org/entity/Q79110656> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- Q79110656 description "clinical trial" @default.
- Q79110656 description "ensayu clínicu" @default.
- Q79110656 description "klinisch onderzoek" @default.
- Q79110656 description "клінічне випробування" @default.
- Q79110656 name "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" @default.
- Q79110656 name "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" @default.
- Q79110656 type Item @default.
- Q79110656 label "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" @default.
- Q79110656 label "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" @default.
- Q79110656 prefLabel "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" @default.
- Q79110656 prefLabel "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" @default.
- Q79110656 P1132 Q79110656-75945C77-50B3-4A80-B70E-7C86D46B83BE @default.
- Q79110656 P1476 Q79110656-10458E87-F6B9-4EEB-A3C1-D50058A4C3C3 @default.
- Q79110656 P17 Q79110656-2041091C-D6E3-4446-AE84-C36D09BDFF5B @default.
- Q79110656 P17 Q79110656-21D2A5AB-7B73-4E66-9F2B-A3B21F33FF67 @default.
- Q79110656 P17 Q79110656-33550D95-41B1-415A-87F8-5BA9DD0A83BF @default.
- Q79110656 P17 Q79110656-4824BA1F-C32C-478F-81EC-A4C1812791CA @default.
- Q79110656 P17 Q79110656-49135002-1234-4BCC-8A1A-1365818E1903 @default.
- Q79110656 P17 Q79110656-557B2FF5-E276-49FF-A3ED-03B3CC252D4F @default.
- Q79110656 P17 Q79110656-60297D14-D35A-4566-ACB0-843C8B53BD4F @default.
- Q79110656 P17 Q79110656-67222B82-5533-4B49-9C8C-283E16E95128 @default.
- Q79110656 P17 Q79110656-71A7F8F3-7062-46CB-9A1A-AEC6C00760B3 @default.
- Q79110656 P17 Q79110656-82F25A7F-1911-49F6-894B-B44E68E9247D @default.
- Q79110656 P17 Q79110656-862681C7-1290-4307-BAF3-A7149A38AD3B @default.
- Q79110656 P17 Q79110656-9283D033-64DD-4E97-B16F-8D7961AF0A45 @default.
- Q79110656 P17 Q79110656-9B31967B-653A-4F21-9C11-66CD56136490 @default.
- Q79110656 P17 Q79110656-AB18224B-1DC3-402B-BF12-72D274540395 @default.
- Q79110656 P17 Q79110656-ADE94CFB-1941-4650-8837-C87775FBE36A @default.
- Q79110656 P17 Q79110656-B1F4D52B-6BA7-4CCB-A0AB-B0B451980462 @default.
- Q79110656 P17 Q79110656-B24F7ED2-EC5A-431B-AAC2-018D51A66D78 @default.
- Q79110656 P17 Q79110656-C8E155E0-D912-41A1-8E64-F54A9F9F34EE @default.
- Q79110656 P17 Q79110656-E6CF282C-48D7-47AD-912D-979A55CF82F1 @default.
- Q79110656 P17 Q79110656-E6E90B07-706C-41C6-B652-2AAC03975FB1 @default.
- Q79110656 P17 Q79110656-E7055869-AB8C-47F3-8DB3-3890B01F71B4 @default.
- Q79110656 P1813 Q79110656-86D66296-E2DA-4A92-96D4-6818A4F21E00 @default.
- Q79110656 P2899 Q79110656-0BB7B927-42F0-472C-B4A6-542CDCB4C80A @default.
- Q79110656 P3098 Q79110656-9373A70F-24C7-42B7-9317-9832E9D5BA32 @default.
- Q79110656 P31 Q79110656-8D4FDA7A-83FD-4513-A8D5-69678FB998EA @default.
- Q79110656 P4844 Q79110656-3C72A55D-FB90-41BE-A3A8-B161CAD1536B @default.
- Q79110656 P4844 Q79110656-88D1991D-DEDF-4168-8E87-9D6F9729E809 @default.
- Q79110656 P4844 Q79110656-97EBBD20-B4BD-4B92-B820-EF1957B2227F @default.
- Q79110656 P4844 Q79110656-FB15847C-D065-4DFE-9FD7-1ADAC61758A3 @default.
- Q79110656 P580 Q79110656-E13F7BF6-C21D-47D7-B702-6BF5913D4497 @default.
- Q79110656 P582 Q79110656-B157232A-5869-46FE-9B10-73DE88BF3930 @default.
- Q79110656 P6099 Q79110656-22573808-D0B6-42D6-99BE-D7D106BADBA3 @default.
- Q79110656 P8363 Q79110656-05AD388D-F75F-4046-BAAA-E6BE657908E7 @default.
- Q79110656 P1132 "+400" @default.
- Q79110656 P1476 "LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer" @default.
- Q79110656 P17 Q142 @default.
- Q79110656 P17 Q145 @default.
- Q79110656 P17 Q155 @default.
- Q79110656 P17 Q16 @default.
- Q79110656 P17 Q183 @default.
- Q79110656 P17 Q212 @default.
- Q79110656 P17 Q218 @default.
- Q79110656 P17 Q29 @default.
- Q79110656 P17 Q30 @default.
- Q79110656 P17 Q31 @default.
- Q79110656 P17 Q334 @default.
- Q79110656 P17 Q36 @default.
- Q79110656 P17 Q38 @default.
- Q79110656 P17 Q408 @default.
- Q79110656 P17 Q41 @default.
- Q79110656 P17 Q43 @default.
- Q79110656 P17 Q55 @default.
- Q79110656 P17 Q801 @default.
- Q79110656 P17 Q8646 @default.
- Q79110656 P17 Q865 @default.
- Q79110656 P17 Q96 @default.
- Q79110656 P1813 "LIBRETTO-431" @default.
- Q79110656 P2899 "+18" @default.
- Q79110656 P3098 "NCT04194944" @default.
- Q79110656 P31 Q30612 @default.
- Q79110656 P4844 Q13896859 @default.
- Q79110656 P4844 Q412415 @default.
- Q79110656 P4844 Q415220 @default.
- Q79110656 P4844 Q415588 @default.
- Q79110656 P580 "2019-12-10T00:00:00Z" @default.
- Q79110656 P582 "2023-12-13T00:00:00Z" @default.
- Q79110656 P6099 Q42824827 @default.
- Q79110656 P8363 Q78089383 @default.